Studies showed the various treatments improved symptoms, but more trials need to be done.
This article was originally published on Dermatology Times. It has been lightly edited.
Researchers reviewed 35 studies of medical treatments for hidradenitis suppurativa (HS) in patients younger than 18 years and found that treatments improved HS symptoms, but the results were unclear as to the extent of improvement.1
Of the 101 patients included in the studies, 50 were overweight or obese. Of the 17 studies that included Hurley stages, most patients had Hurley Stage II disease (46.7%), followed by Stage I (36%), and Stage III (17.3%). The studies took place across 16 countries, and included 29 case studies/reports, 5 prospective trials, and 1 retrospective cohort study.
Medical treatment included biologics (n = 17), oral retinoids (n = 7), oral antibiotics (n = 5), antiandrogen drugs (n = 2), metformin (n = 2), antiretroviral therapy (n = 1), and thalidomide (n = 1). Ages of patients ranged from 17 months to 17 years.
Of the studies of various oral antibiotic treatments reporting a response rate, 100% showed improvement in HS symptoms based on the Sartorius score. Hurley Stages I, II, and III were represented in the cohort.
Finasteride reduced frequency and intensity of symptoms for all patients on the regimen. After 2 patients discontinued taking the drug, they responded favorably when it was reintroduced. “Pediatric patients with HS are more likely to have hormonal imbalances compared with the general pediatric population,” the study authors noted.1 It is possible that finasteride improved HS symptoms by decreasing the conversion of testosterone to dihydrotestosterone.
Of the patients treated with biologics, 93.9% showed improvement. The biologics studied included adalimumab, infliximab, anakinra, etanercept, and ustekinumab. Patients treated had Hurley Stage II or Hurley Stage III.
In the 2 studies of metformin, 50% of patients responded favorably to treatment. Hurley Stages II and III were represented in the cohort.
Patients treated with oral retinoids showed a response rate of 80%. Adverse events reported with oral retinoids included cheilitis, xerosis, dry mouth, headaches, arthralgias, and acne.
Treatment with thalidomide resulted in no improvement and antiretroviral therapy resulted in improvement in the 1 patient who was treated.
Medical treatments for HS showed overall improvement, but investigators emphasized the importance of including pediatric patients in studies examining effectiveness of treatments for HS.
Reference
Masson R, Ma E, Parvathala N, et al. Efficacy of medical treatments for pediatric hidradenitis suppurativa: a systematic review. Pediatr Dermatol. Published online August 1, 2023. doi:10.1111/pde.15404
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More